RAPT Therapeutics Files 8-K on Director Changes and Compensation
| Field | Detail |
|---|---|
| Company | Rapt Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | May 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
TL;DR
RAPT Therapeutics filed an 8-K today covering board changes and executive pay. Keep an eye on governance.
AI Summary
On May 29, 2025, RAPT Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also covers the submission of matters to a vote of security holders, indicating potential corporate actions or shareholder decisions.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Numbers
- 001-38997 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3313701 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- RAPT Therapeutics, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 561 Eccles Avenue, South San Francisco, California 94080 (address) — Principal Executive Offices
- FLX Bio, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates 'Departure of Directors or Certain Officers' and 'Election of Directors' as items covered, but does not specify the names or details of the individuals involved in the 8-K text provided.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not elaborated in the provided text.
What matters were submitted to a vote of security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' as an item, but the nature of these matters is not detailed in the provided text.
When was RAPT Therapeutics, Inc. formerly known as FLX Bio, Inc.?
The date of the name change from FLX Bio, Inc. to RAPT Therapeutics, Inc. was May 4, 2016.
What is the primary business of RAPT Therapeutics, Inc. according to the filing?
The Standard Industrial Classification code provided is 'PHARMACEUTICAL PREPARATIONS [2834]', indicating their primary business.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding RAPT Therapeutics, Inc..